{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03424850",
            "orgStudyIdInfo": {
                "id": "201801118"
            },
            "organization": {
                "fullName": "Washington University School of Medicine",
                "class": "OTHER"
            },
            "briefTitle": "Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy",
            "officialTitle": "A Phase I/II Dose-escalation Study Evaluating the Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "safety-and-efficacy-of-gy-gy-and-gy-for-high-dose-rate-hdr-prostate-brachytherapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-02-27",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-02-28",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-02-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-01-23",
            "studyFirstSubmitQcDate": "2018-01-31",
            "studyFirstPostDateStruct": {
                "date": "2018-02-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Washington University School of Medicine",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research study is to learn more about the outcomes and early and late side effects of treating early stage prostate cancer with high dose rate brachytherapy."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer",
                "Prostate Neoplasm"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "HDR brachytherapy - 21 Gy",
                    "type": "EXPERIMENTAL",
                    "description": "-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 21 Gy.",
                    "interventionNames": [
                        "Radiation: HDR brachytherapy"
                    ]
                },
                {
                    "label": "HDR brachytherapy - 23 Gy",
                    "type": "EXPERIMENTAL",
                    "description": "-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 23 Gy.",
                    "interventionNames": [
                        "Radiation: HDR brachytherapy"
                    ]
                },
                {
                    "label": "HDR brachytherapy - 25 Gy",
                    "type": "EXPERIMENTAL",
                    "description": "-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 25 Gy.",
                    "interventionNames": [
                        "Radiation: HDR brachytherapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "RADIATION",
                    "name": "HDR brachytherapy",
                    "description": "* Dose constraints for 21 Gy:\n\n  * Bladder and rectum: V70 \\< 1 cc\n  * Urethra: V115 \\< 1 cc\n  * V135: 0%\n* Dose constraints for 23 Gy:\n\n  * Bladder and rectum: V65 \\< 1 cc\n  * Urethra: V105 \\< 1 cc\n  * V125: 0%\n* Dose constraints for 25 Gy:\n\n  * Prostate V100 \\>90% (\\>95% preferred)\n  * Bladder and rectum: V70 \\< 1 cc, Dmax \\<115%\n  * Urethra: V110 \\< 1 cc, Dmax \\<120%",
                    "armGroupLabels": [
                        "HDR brachytherapy - 21 Gy",
                        "HDR brachytherapy - 23 Gy",
                        "HDR brachytherapy - 25 Gy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Biochemical control experienced by patients with prostate cancer treated with an HDR implant",
                    "description": "-Response will be determined by PSA. The Phoenix definition will be used for determining biochemical failure: a rise of 2 ng/mL or more above the PSA nadir",
                    "timeFrame": "Through 3 years after implant"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Rate of acute toxicity experienced by patients with prostate cancer treated with an HDR implant",
                    "description": "-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.",
                    "timeFrame": "From start of treatment through 90 days"
                },
                {
                    "measure": "Rate of late toxicity experienced by patients with prostate cancer treated with an HDR implant",
                    "description": "-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.",
                    "timeFrame": "From day 91 through 3 years after implant"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Optimal dose of radiation",
                    "description": "-The optimal dose is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity within the DLT assessment period (3 months after implant) OR the maximally administered dose if fewer than 2 patients in that cohort experience DLT.",
                    "timeFrame": "Through 3 months after completion of implant for all patients enrolled (estimated to be 5 years and 3 months)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of early stage prostate cancer.\n* Must be considered either low-risk (T1-T2a, Gleason \u2264 6, PSA \\< 10 ng/mL) or favorable intermediate-risk (Gleason 3 +4 = 7, percentage of positive biopsy cores \\< 50%, no more than one NCCN intermediate risk factor).\n* Prior androgen deprivation therapy is allowed and may have been initiated up to 6 months prior to the date of the HDR implant. The complete duration of androgen deprivation therapy can range from 4 months to 36 months provided it has been initiated no more than 6 months prior to the date of the HDR implant.\n* At least 18 years of age.\n* ECOG performance status \u2264 2\n* Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nExclusion Criteria:\n\n* Prior radiation therapy to the prostate or lower pelvis encompassing the prostate.\n* A history of other malignancy \u2264 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only.\n* Currently receiving any other investigational agents.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.\n* Unable to undergo general, spinal or local anesthesia.\n* Prior TURP with a sufficiently large defect that would compromise the integrity of the implant per clinician's assessment.",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Hiram A Gay, M.D.",
                    "role": "CONTACT",
                    "phone": "314-362-8516",
                    "email": "hiramgay@wustl.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Hiram A Gay, M.D.",
                    "affiliation": "Washington University School of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hiram A Gay, M.D.",
                            "role": "CONTACT",
                            "phone": "314-362-8516",
                            "email": "hiramgay@wustl.edu"
                        },
                        {
                            "name": "Hiram A Gay, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Jeff M Michalski, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Joshua Schiff, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Yi Huang",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Michael Altman, Ph.D.",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine",
                    "url": "http://www.siteman.wustl.edu"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Neoplasm",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}